Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets
Cycle Pharmaceuticals (“Cycle”), a global pharmaceutical company focused on rare diseases, and Forma Life Sciences, Inc. (“Forma”), a U.S. contract development and manufacturing organization, today announced a commercial manufacturing agreement for CAVHANZA™ (nilotinib) orally disintegrating tablets.
Forma Life Sciences Launches U.S. Based Contract Development and Manufacturing Organization (CDMO) for Oral Solid Dosage Development and Commercial Manufacturing in Irvine, California
Forma Life Sciences, Inc. today announced its launch as an independent, operator-owned contract development and manufacturing organization (CDMO) focused on oral solid dosage formulation development, clinical manufacturing, and commercial drug product manufacturing in the United States.
